Xinhuanet News on December 4: Viwit Pharmaceutical Innovation Leads, Helping the Construction of Healthy China!
This year, Viwit Pharmaceutical*** was selected into the list of 2023 (the 30th batch) of the National Enterprise Technology Center to be recognized. Since its establishment in 2006, Viwit has always regarded technological innovation as the fundamental lifeblood of enterprise development, and insisted on taking innovation as the first driving force to lead the development of the enterprise. As one of the leading and backbone enterprises in the new pharmaceutical industry in Shandong Province, Viwit actively undertakes scientific and technological innovation projects of ** departments at all levels, builds technological innovation platforms, and continuously explores in the field of medicine and health. The selection of the National Enterprise Technology Center reflects Viwit's R&D, technology and innovation achievements, as well as innovation drive.
In order to implement the "Healthy China 2030 Planning Outline", Viwit has broken through a number of technical barriers and independently developed the smoking cessation drug "Weili Jie" for 5 years. The products independently developed by Viwit Pharmaceutical, such as MRI contrast agents, tumor-targeting drugs** drugs and some varieties of ophthalmic drugs, are all in the stage of registration application or clinical research, and will be launched one after another.
In terms of talent mining, Viwit Pharma jumped out of the traditional talent introduction model, played a new card of "attracting talents with talents", paid attention to talent introduction and training, and established an international team led by high-level talents. Viwit now has more than 30 experts who have won the honor of provincial and above talents, including high-level experts and 6 Taishan industry leading talents. Viwit has been awarded the titles of "Advanced Unit of Talent Work" and "Outstanding Unit of Talent Work" at the provincial level for three times.
In the future, Viwit will build a first-class enterprise technology center, continue to strengthen investment in technological innovation, strengthen the construction of technical talents, improve the ability of transformation of R&D achievements and independent innovation, and strive to build a pharmaceutical and health industry chain system that serves the clinical needs of the public, so as to promote the development of China's pharmaceutical industry, contribute to the construction of a healthy China, and build a happy and harmonious society.